These biotech stocks are getting hammered by shocking brittle-bone treatment study results
MarketWatch·2025-12-30 02:05

公司股价表现 - Ultragenyx与Mereo BioPharma股价均因setrusumab令人失望的试验结果而遭遇创纪录的抛售 [1]

These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Reportify